Overcoming Chemoresistance in Cancer: Identifying Biomarkers and Novel Targets
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 1 March 2025 | Viewed by 79
Special Issue Editors
Interests: cancer; chemoresistance; nucleolar stress; extra-ribosomal function of ribosomal proteins; cell cycle
Special Issues, Collections and Topics in MDPI journals
Interests: tumorigenesis; cancer therapy; TP53; ribosomal stress; extra-ribosomal function of ribosomal proteins
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The development of chemoresistance remains the main obstacle in the successful treatment of cancer. There is no doubt that a great deal of work has been done in the last few years to increase our understanding of the mechanisms behind the development of drug resistance in cancer. However, the identification of new targets is crucial for the development of personalized therapeutic strategies aiming to overcome chemoresistance.
In this Special Issue of Cancers, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: the identification of novel molecular mechanisms of chemoresistance; the discovery of novel molecular biomarkers to allow cancer patient stratification and personalized treatment; the discovery of new drug targets; and the development of novel combined treatments targeting multiple signaling pathways.
We look forward to receiving your contributions.
Dr. Annapina Russo
Dr. Giulia Russo
Dr. Annalisa Pecoraro
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer treatment
- chemoresistance
- tumor microenvironment
- cancer signaling pathways
- targeted therapy
- personalized anti-cancer therapies
- biomarker
- anti-cancer drug response prediction
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
